Abstract: PO0049
Risk Factors for RRT and Mortality in Patients with COVID-19-Related AKI in São Paulo, Brazil
Session Information
- COVID-19: Epidemiology, Outcomes, Complications, and Risk Factors
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Almeida, Carlos Augusto Pereira de, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Arantes de Oliveira, Marcia Fernanda, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Sandoval Cabrera, Carla Paulina, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Teixeira, Alexandre Macedo, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Espinosa Armijos, Jorge Leonardo, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Valle, Eduardo de Oliveira, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Reichert, Bernardo V., University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Sales, Gabriel Teixeira Montezuma, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Smolentzov, Igor, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Strufaldi, Fernando Louzada, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Lins, Paulo Ricardo Gessolo, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Rodrigues, Camila Eleuterio, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Seabra, Victor F., University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
- Andrade, Lucia, University of Sao Paulo School of Medicine, Sao Paulo, Sao Paulo, Brazil
Background
In COVID-19, as in SARS, the degree of kidney injury can have major implications for the clinical outcomes. Early reports indicate that, among patients with COVID-19, AKI is common and is associated with worse outcomes. However, COVID-19-related AKI among ICU patients in Brazil has not been well described.
Methods
This was a retrospective observational study of the electronic health records of patients with COVID-19-related AKI admitted to the Hospital das Clínicas in the city of São Paulo, Brazil, between March and August of 2020. We applied only KDIGO criteria 2 and 3. We used logistic regression to analyze risk factors for the composite outcome of mortality or RRT.
Results
Among the 694 patients with COVID-19-related AKI, the mean age was 63 years and mortality was 66.4%; 41% needed vasoactive drugs, 66% needed mechanical ventilation, and 72% needed dialysis. Univariate analysis showed the following risk factors for mortality and RRT at admission: male sex; diabetes; CKD; vasoactive drug use; mechanical ventilation; acidemia; elevated lactate, magnesium, potassium, creatinine, C-reactive protein, creatine phosphokinase, total bilirrubin; proteinuria; hematuria; and increased fractional excretion of potassium (n=98) and sodium (n=110). The factors that remained significant in the multivariate analysis were male sex, vasoactive drug use, serum magnesium >2.5 mg/dL and oliguria (24-h urine output <500 mL).
Conclusion
In ICU patients with COVID-19-related AKI, in Brazil and elsewhere, in-hospital mortality is high. The exact mechanism by which hypermagnesemia increases mortality in such patients merits further study. Supported by FAPESP.
Risk factors for mortality or RRT in patients with COVID-19-related AKI in Brazil
Univariate analysis | P | Multivariate analysis | P | |
OR (95% CI) | OR (95% CI) | |||
Age, per year increase | 1.01 (1-1.02) | 0.13 | 1 (0.99-1.02) | 0.66 |
Male sex | 1.74 (1.15-2.62) | 0.008 | 1.86 (1.2-2.9) | <0.01 |
Serum creatinine at ICU admission, per unit increase | 1.12 (1.01-1.25) | 0.004 | 1.03 (0.94-1.14) | 0.61 |
Vasopressor use at admission | 2.96 (1.71-5.43) | <0.001 | 4.07 (2.35-7.46) | <0.001 |
Serum magnesium > 2.5 mg/dL | 3.54 (2.08-6.2) | <0.001 | 2.09 (1.1-4.36) | 0.03 |
Oliguria | 0.99 (0.99-0.99) | 0.005 | 3.31 (1.83-6.44) | <0.001 |
Funding
- Government Support – Non-U.S.